ARLINGTON, Va. (PRWEB) December 28, 2022
In 2022, Indonesia’s in vitro diagnostic (IVD) market is estimated to be about $812 million. The nation’s leading IVD segments 2022 are point-of-care (POC) testing and microbiology and virology. The microbiology and virology segment includes immunoassays as well as molecular assays for infectious diseases including COVID-19 tests. Kalorama Information's finding was made in its latest report on in vitro diagnostic markets in select APAC nations, In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022.
Indonesia is an archipelago spread across over 17,000 islands, which offers significant challenges to implement healthcare infrastructure across the country. However, the living conditions and access to health services have been improving in the country during the past few decades. For instance, the life expectancy at birth was reported to have increased to 71.5 in 2018 from 62.3 in 1990.
Changing lifestyles and environment have influenced the pattern of diseases in Indonesia. Non-communicable diseases (NCDs) account for 73% of all deaths currently, with most common diseases including stroke, cancer, heart diseases, diabetes, liver diseases, and lung diseases. According to the 2018 report of National Basic Health Research, over 34% of the population are suffering from high blood pressure and more than 35% of the population is classified to be obese.
The healthcare system in Indonesia has public and private components. The public health system is decentralized, with responsibilities dispersed between central, provincial and district levels of government. The Ministry of Health (MOH) manages specialist hospitals in addition to setting standards, regulating the sector, ensuring human resources availability, and more. Provincial governments are in charge of provincial as well as district healthcare services and manage cross-district matters. City hospitals and community primary health centers (known as puskesmas in Indonesia) are managed by the district and municipal governments.
Kalorama Information’s report finds that Indonesia’s healthcare system is strained by the outbreaks of communicable diseases as well, in addition to NCDs. Most prevalent communicable diseases in the country include HIV, malaria, dengue, and typhoid, among others. The country was also affected significantly due to the outbreak of COVID-19 in 2020. The growing prevalence of NCDs posed additional challenges during the pandemic as managing COVID-19 patients with underlying conditions such as diabetes, heart diseases, and hypertension became an added challenge for the healthcare system during the pandemic.
About Kalorama Information:
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.